Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Plant-Produced Bivalent Norovirus Vaccine rNV-2v in Healthy Adults
NCT05508178Phase 1Completed
- Sponsor
- Icon Genetics
- Start
- Aug 2020
- Primary completion
- Oct 2021
- Modality
- Recombinant Protein Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of rNV-2v in norovirus gastroenteritis (3 arms), sponsored by Icon Genetics. Primary endpoints: Safety, tolerability, and reactogenicity (7 days), Safety, tolerability, and reactogenicity (Day 57) and 1 more. Started Aug 2020; status: completed.
02
Drugs
rNV-2v
03
Conditions
norovirus gastroenteritis
Beyond the preview
Go deeper on NCT05508178.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05508178.